Published in final edited form as:

Respir Care. 2012 November ; 57(11): . doi:10.4187/respcare.01605.

Isoflurane for Life-Threatening Bronchospasm – A 15 Year Single-Center Experience

David A. Turner, MD¹, David Heitz, RRT², Mehrengise K. Cooper, FRCPH³, P. Brian Smith, MD, MPH, MHS⁴, John H. Arnold, MD⁵, and Scot T. Bateman, MD⁶

¹Division of Pediatric Critical Care Medicine, Department of Pediatrics, Duke Children's Hospital, Duke University Medical Center, Durham, NC

²Respiratory Care Services, Children's Hospital of Atlanta, Atlanta, GA

³Consultant Paediatric Intensivist, Saint Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK

⁴Duke Clinical Research Institute, Duke University Medical Center, Durham, NC

⁵Department of Anesthesia (Pediatrics), Children's Hospital, Boston, MA

⁶Division of Pediatric Critical Care Medicine, Department of Pediatrics, UMass Memorial Medical Center, Worcester, MA

Abstract

Introduction—Children with severe bronchospasm requiring mechanical ventilation may become refractory to conventional therapy. In these critically ill patients, isoflurane is an inhaled anesthetic agent available in some centers to treat bronchospasm. We hypothesized that isoflurane is safe and would lead to improved gas exchange in children with life-threatening bronchospasm refractory to conventional therapy.

Methods—A retrospective review was conducted and included mechanically ventilated children treated with isoflurane in a quaternary pediatric intensive care unit for life-threatening bronchospasm from 1993–2007. Demographic, blood gas, ventilator and outcome data were collected.

Results—Thirty-one patients with a mean age of 9.5 years (range; 0.4 – 23 years) were treated with isoflurane from 1993–2007. Mean time to initiation of isoflurane after intubation was 13 hours (0–120 hours) and the mean maximum isoflurane dose was 1.1 % (0.3 – 2.5%). Mean duration of isoflurane administration was 54.5 hours (1 – 181), with a total mean duration of mechanical ventilation of 252 hours (33.3 – 1454.5). Isoflurane led to significant improvement in pH and pCO₂ within four hours of initiation (p = 0.001). Complications during isoflurane administration included hypotension requiring vasoactive infusions in 24 (77%), arrhythmia in 3 (10%), neurologic side effects in 3 (10%), and pneumothorax in 1 (3%) patient.

Conclusions—Isoflurane led to improvement in pH and pCO₂ within four hours in this series of mechanically ventilated patients with life-threatening bronchospasm. The majority of patients in this series developed hypotension, but there was a low incidence of other side effects related to isoflurane administration. Isoflurane appears to be an effective therapy in patients with life-

Corresponding Author: David A. Turner, MD, DUMC Box 3046, Durham, NC 27710, Phone: 1(919) 681-3550, Fax: 1(919) 681-8357, david.turner@duke.edu.

Disclosures: None

Conflicts of Interest: None

threatening bronchospasm refractory to conventional therapy. However, further investigation is warranted given the uncertain overall impact of isoflurane in this context.

Keywords

asthma; bronchospasm; mechanical ventilation; inhaled anesthetics; isoflurane; pediatric intensive care unit

Introduction

Over nine million children in the United States suffer from asthma, making it the most common chronic disease of childhood ¹. Despite significant public health efforts and medical advances over the past several years, the prevalence and mortality of pediatric asthma remains largely unchanged ². Morbidities related to childhood asthma lead to more than six million office visits, 700,000 emergency department visits, 200,000 hospitalizations, and 200 deaths each year ².

Children who present with life-threatening episodes of bronchospasm requiring intubation and intensive care unit (ICU) admission represent a small fraction of asthma exacerbations, but the care of these patients is the source of substantial health care cost and considerable complications ³. The treatment of these patients with bronchospasm and acute respiratory failure who require mechanical ventilation is often challenging, and difficulty in controlling the ventilation of bronchospastic lungs is often particularly troublesome. These patients sometimes become refractory to conventional therapies, leading some centers to employ inhaled anesthetic agents to aid in achievement of adequate gas exchange in these most severely affected patients ⁴⁻¹¹.

Inhaled anesthetics have inherent bronchodilatory properties that are the pharmacologic basis for their administration as a therapeutic option for bronchospasm. In addition, the anesthetic properties of these medications provide excellent sedation for these patients to assist with facilitation of mechanical ventilation. Inhaled agents produce bronchodilation both directly via relaxation of airway smooth muscle cells and indirectly through the depression of protective airway reflexes ^{12, 13}. Isolated reports of inhaled anesthetics for the treatment of refractory bronchospasm in adult patients can be found as early as the 1930s ¹⁴⁻¹⁶, and through the 1970s, a number of investigators reported the use of halothane, enflurane, sevoflurane, or isoflurane in adult patients with asthma refractory to traditional therapies and asthmatic patients needing general anesthesia ^{4-7, 17}. This use of inhaled anesthetics in the context of bronchospasm expanded to pediatric patients in the 1980s and 1990s, however, use of these agents continues to remain limited ⁸⁻¹¹.

Isoflurane has become somewhat more prevalent than other inhaled anesthetics as a therapeutic option for refractory bronchospasm over the past decade in the Pediatric Intensive Care Unit (PICU), primarily due to its safety profile relative to other agents ¹⁸⁻²⁰. However, the use of inhaled anesthetics outside of the operating room remains relatively uncommon, due to the need for both experienced providers and appropriate equipment for the delivery and scavenging of these volatile agents. Inhaled anesthetics, like isoflurane, present significant challenges in the PICU setting given their volatility and potential impact on bedside providers, but in recent years, growing interest has emerged in expansion of the administration of inhaled anesthetics for a wide range of applications in the PICU ^{18, 19}. In addition, improved integration of ventilator technology and capabilities in modern anesthesia machines may allow for safer delivery of these agents in a wider range of clinical settings. We undertook this retrospective review to describe our experience with the use of

isoflurane for life-threatening bronchospasm in the PICU at our institution over a 15 year period.

Methods

After Children's Hospital Boston Institutional Review Board approval, the medical records of all patients with life-threatening bronchospasm and acute respiratory failure necessitating endotracheal intubation and mechanical ventilation who were treated with isoflurane from January 1993 through December 2007 at the PICU at Children's Hospital Boston were identified from a respiratory therapy database. Records were reviewed with attention to demographic information, diagnosis, dosing, and duration of isoflurane administration. We also recorded all blood gas measurements, duration of mechanical ventilation, outcome, and need for ongoing respiratory support upon discharge. Further data were collected related to side effects attributable to isoflurane which included hypotension (defined as the need for vasoactive medications to support blood pressure despite fluid administration following initiation of isoflurane), air leak, arrhythmia, and neurologic dysfunction (defined as any new neurologic finding or abnormality during isoflurane administration).

Following intubation, all patients were treated with pressure limited ventilation. While no ventilator guideline or protocol was used for these patients, in general, the approach to mechanical ventilation was to minimize lung injury by allowing permissive hypercapnea, while also minimizing both mean airway pressure (MAP) and fraction of inspired oxygen (FiO_2). Ventilatory strategies, along with all other management decisions ultimately were made by the pediatric intensivist led clinical team caring for the patient at the bedside. Therapies utilized in all patients included both inhaled beta-agonists and intravenous steroids, and most patients were also treated with a number of other adjunctive agents. These additional interventions included intravenous beta-agonists, inhaled ipratropium bromide, intravenous methylxanthines, intravenous magnesium sulfate, and intravenous ketamine.

Isoflurane was initiated at the discretion of the care team based on clinical progression and trajectory. Prior to initiation of isoflurane, family and anesthetic histories were taken and patients with a personal or family history of malignant hyperthermia or myopathy were not treated with isoflurane. Starting dose was determined by the clinical team, and there was no standard protocol for isoflurane initiation and titration, but in general, the goal was to maintain a minimal alveolar concentration (MAC) of approximately 0.5 to 1.0 MAC. A MAC of 1.0 represents the dose sufficient to prevent movement upon surgical incision in 50 % of patients. Isoflurane was administered in all cases using an isoflurane vaporizer and self-scavenging system fitted to a Siemens Servo 900 C Ventilator (Maquet Inc., Bridgewater, NJ). The Datex Ohmeda Ultima (Soma Technology, Bloomfield, CT) agent monitor was used for continuous measurement of end tidal carbon dioxide as well as inspired and expired isoflurane concentrations during administration.

Isoflurane dosing was followed and titrated using the alveolar concentration (%) measured in the expiratory limb of the ventilator circuit, with an exhaled isoflurane concentration of 1.6% corresponding to 1.0 MAC. Isoflurane was titrated at the discretion of the clinical team. Weaning was initiated once the patient demonstrated improvements in both ventilation and mechanical ventilation settings. After discontinuation of isoflurane, weaning of mechanical ventilation and extubation were guided by patient improvement as determined by the multidisciplinary team.

Statistical analysis

We used non-parametric methods to compare ventilator settings and blood gas values over time. We used univariable linear regression to describe the relationship between time on

isoflurane, dose of isoflurane, age, and sex to the change in ventilator settings and blood gas values. A two-sided p value <0.05 was considered statistically significant. STATA 11.0 (College Station, TX) was used for statistical analyses.

Results

During the study period, 31 patients requiring mechanical ventilation for life-threatening bronchospasm were treated with isoflurane (Table 1). The mean duration of mechanical ventilation prior to initiation of isoflurane was 13 hours (Table 2). Mean initial isoflurane dose was an expired alveolar concentration of 0.7% (0.2 – 2), and mean duration of isoflurane administration was 54 hours. Duration of mechanical ventilation after discontinuation of isoflurane was a mean of 180 hours (0.3 – 1430) (Table 2). The mean baseline pH and $p\text{CO}_2$ were 7.13 (6.89 – 7.41) and 87 mmHg (50 – 160), respectively (Table 3). At the time of initiation of isoflurane, mean ventilator settings included a peak inspiratory pressure (PIP) 33 cmH₂O (24 – 46), positive end expiratory pressure (PEEP) 6 cmH₂O (3 – 10), mean airway pressure 13 cmH₂O (8 – 24), and a mean FiO_2 of 0.74 (0.40 – 1.0). Eight patients (26%) were being treated with an FiO_2 of 1.0 at baseline.

Within four hours of initiation of isoflurane, there was significant improvement in pH and $p\text{CO}_2$ from baseline, and significant decrease in HCO_3 ($p = 0.01$, Table 3, Figures 1 and 2). Between 4 and 24 hours of treatment with isoflurane, pH continued to improve ($p < 0.001$, Table 3), but there was no significant change in $p\text{CO}_2$ ($p = 0.07$) or HCO_3 ($p = 0.06$). For those patients treated more than 24 hours, there continued to be improvement in pH and HCO_3 ($p < 0.01$), but no change in $p\text{CO}_2$ ($p = 0.12$) for the duration of therapy (Table 3, Figures 1 and 2).

Higher maximum isoflurane doses (as measured by the expired alveolar concentration) were not associated with an improvement in $p\text{CO}_2$ or pH during isoflurane administration. There were also no differences in pH, $p\text{CO}_2$, or any ventilator parameter during isoflurane administration related to either age or sex.

In regard to ventilator parameters, peak inspiratory pressure (PIP) did not change in the first four hours of therapy with isoflurane ($p = 0.62$, Table 3). However, from 4 to 24 hours, there was a statistically significant decrease in PIP from a mean of 32 cmH₂O at 4 hours to a mean of 28 cmH₂O at 24 hours ($p = 0.006$, Table 3). For patients treated with isoflurane for longer than 24 hours, there was no change in PIP between 24 hours and the end of therapy ($p = 0.73$). Higher doses of isoflurane were not associated with a change in PIP ($p = 0.23$). FiO_2 decreased within four hours of initiation of isoflurane ($p < 0.001$) and continued to improve from 4 to 24 hours ($p = 0.02$). There was no change in FiO_2 from 24 hours until the end of therapy in those patients treated beyond 24 hours ($p = 0.12$, Table 3).

Hypotension (defined as a drop in blood pressure not responsive to fluid administration and necessitating vasoactive agent administration) was the most common side effect in this series and developed after isoflurane initiation in 24 (77%) patients. Other than the initiation of isoflurane, there were no other clinical changes or diagnoses felt to be contributing to this blood pressure instability. Most of these 24 patients were treated with dopamine monotherapy (79%), and the remainder were treated with varying combinations of dopamine, epinephrine, and phenylephrine. (Table 4) Mean time to vasoactive agent initiation after starting isoflurane was 3 hours (0 – 16), and the mean maximum dose of dopamine used in these patients was 13.6 $\mu\text{g/kg/min}$ (2.5 – 20). The mean expiratory alveolar concentration isoflurane dose upon vasoactive agent initiation was 0.6 % (0.1 – 1.5). There was no difference between the maximum dose of isoflurane in patients who developed hypotension and those who did not ($p=0.63$). Fifteen of the 24 hypotensive

patients (63%) had vasoactive agents discontinued prior to discontinuation of isoflurane, and there was no difference between the isoflurane dose upon initiation of vasoactive medications (0.7%) when compared to the dose when vasoactive infusions were discontinued (0.6%).

Additional side effects during isoflurane administration included cardiac side effects in three patients. These cardiac effects encountered during isoflurane administration included one patient with supraventricular tachycardia responsive to treatment with verapamil, one patient with self-limited ST segment changes associated with a transient rhythm disturbance that was not hemodynamically significant and self-limited, and one patient with self-limited arrhythmias in the setting of having a pacemaker for underlying baseline dysrhythmias. In addition, three patients also developed neurologic side effects thought to be related to isoflurane which included abnormal movements in two patients and withdrawal symptoms in one additional patient. All of these neurologic symptoms resolved upon discontinuation of isoflurane. Three patients had chest tubes in place prior to isoflurane initiation, and new pneumothorax was noted in one patient during administration of isoflurane. The pneumothorax developed in a patient who required treatment with PIPs of greater than 45 mmHg for approximately 24 hours after initiation of isoflurane. Despite these ventilatory requirements, PCO₂ remained greater than 100 mmHg until approximately 24 hours after initiation of mechanical ventilation and isoflurane.

Of the six patients treated with isoflurane for > 100 hours, four of them developed either arrhythmia, neurologic side effects and/or pneumothorax. No additional side effects or complications related to isoflurane administration were noted. There were also no recorded difficulties or complications for staff members caring for patients being treated with isoflurane.

Twenty-nine of the 31 patients (94%) survived to hospital discharge. Upon discharge, 4 of the 29 survivors required ongoing treatment with oxygen, although the etiology of this persistent oxygen requirement was unclear. In the 2 non-survivors, durations of mechanical ventilation prior to the initiation of isoflurane were 103 and 96 hours, and only one patient who survived in this series underwent mechanical ventilation prior to isoflurane initiation for longer than the two non-survivors (120 hours).

Discussion

Patients with respiratory failure secondary to life-threatening bronchospasm who require mechanical ventilation are an extremely challenging population of PICU patients. These patients may become refractory to conventional therapies, and isoflurane is a potent bronchodilator that has been previously reported as an effective rescue therapy in adult and pediatric patients with severe bronchospasm in these most severely affected patients^{6, 7, 9–11, 20}.

The primary limitation to the use of isoflurane in the PICU setting traditionally has been related to practical difficulties associated with administration of inhaled anesthetic agents outside of the operating room. These difficulties include problems with administration, monitoring, and gas scavenging. However, successful adaptation of standard ventilators has been reported, and recent advances in ventilator technology may facilitate the ease of administration of these agents in the PICU^{10, 20–22}. Despite these advances, the largest reported series to date of isoflurane administration for pediatric patients with asthma is 10 children, published in 2006 by Shankar et al²⁰.

In this series, we administered isoflurane to 31 mechanically ventilated patients with clinical evidence of bronchospasm. The pH, pCO₂, FiO₂ significantly improved within four hours of

initiation of isoflurane, and this response was persistent for the duration of therapy (Table 3, Figures 1 and 2). This improvement is consistent with prior reports documenting rapid improvement of blood gas parameters in bronchospastic patients treated with isoflurane^{10, 20, 22, 23}. Interestingly, an initial worsening of metabolic acidosis was noted in the first four hours of therapy with isoflurane, demonstrating that the pH improvement during this initial time period was related to improvement of ventilation and improvement of respiratory acidosis. These improvements in pH and pCO₂ were sustained over time, but the continued rise in HCO₃ over time likely contributed to the significant ongoing improvement in pH from 4 hours until the end of therapy (Table 3, Figures 1 and 2).

However, the impact of isoflurane dose on hemodynamic status is less clear. Hypotension requiring fluid administration is common following the transition to positive pressure ventilation, especially early in the course of illness, when both airway pressures and sedation are being titrated. However, after initial stabilization, most patients with respiratory failure do not require vasoactive medication administration. We elected to utilize initiation of vasoactive agents as the definition of hypotension in this series in attempt to better establish the impact of isoflurane dosing on blood pressure stability.

Twenty-four of the 31 patients (77%) developed hypotension requiring vasoactive infusions during administration of isoflurane. There was no significant relationship between maximum isoflurane dose and the need for a vasoactive medication for blood pressure support. These data are supported by the fact that 15 of these 24 hypotensive patients (63%) had their vasoactive infusions discontinued while isoflurane continued, with a mean isoflurane dose of 0.6% (0.05 – 1.5) upon vasoactive medication discontinuation. The lack of difference between the isoflurane dose upon initiation of vasoactive infusions (0.7%) and discontinuation of these medications (0.6%) suggests that the vasodilation that occurs upon initiation of isoflurane may be short-lived, self-limited, and not sustained during prolonged administration. This early development of hypotension likely was secondary to vasodilation upon initiation of isoflurane. In these situations, it is possible that blood pressure instability may be mitigated by prompt weaning of other sedating agents or beta-agonists as allowed by the clinical situation for a given patient.

Other than hypotension, there was a relatively low incidence of additional side effects attributable to isoflurane in this series. Most of the safety data on isoflurane in children comes from its use for general anesthesia, but there have been a number of small studies demonstrating the safety of isoflurane for prolonged PICU sedation up to seven days^{24–31}. In these studies, reversible neurologic dysfunction and abstinence syndrome are the most commonly reported side effects^{24, 25, 27, 32}. Three patients in this series developed neurologic side effects, which are well described in the setting of prolonged isoflurane administration^{24, 25, 33}. Two patients developed abnormal movements during isoflurane administration. The maximum isoflurane doses in these patients were 0.8% and 1.8%, which does not suggest a dose-response relationship to neurologic dysfunction related to isoflurane. In addition, the duration of isoflurane administration in these two patients with abnormal movements were 31 and 111 hours, also not clearly demonstrating a relationship between duration of therapy and neurologic side effects. However, broad generalization is impossible given the number of patients with neurologic side effects in this series. The third patient with neurologic side effects developed an abstinence or withdrawal syndrome including restlessness, jitteriness, and agitation upon weaning of isoflurane. The maximum dose of isoflurane in this patient was 1.1%, which was the mean maximum dose in this series, and the duration of isoflurane in this patient was 42 hours, just below the mean duration in this series. Symptoms in all three patients resolved as isoflurane was discontinued. Based on these limited data, it would appear that the neurologic side effects

related to isoflurane administration are idiosyncratic and self-limited upon withdrawal of the agent.

Arrhythmias are another recognized complication of inhaled anesthetics, thought to be largely due to increased myocardial sensitivity to catecholamines associated with these agents³⁴. However, isoflurane has a much lower incidence of arrhythmias when compared to halothane^{34–36}. Three patients in this series developed rhythm disturbance, but one was in a patient with known arrhythmia and an implanted pacemaker. It is possible that the rhythm change in this patient was chronic in nature and unrelated to isoflurane administration. The other two rhythm disturbances in this series were transient, resolved with weaning of isoflurane, and did not recur.

Pneumothorax is another documented complication of mechanical ventilation, and this risk is increased substantially in the setting of bronchospasm and air trapping^{37–39}. In this series, only one patient developed air leak while being treated with isoflurane. Improved gas exchange and decreased levels of ventilatory support secondary to isoflurane administration are potential explanations for the low incidence of pneumothoraces in these patients. However, three patients had chest tubes in place upon initiation of isoflurane, and the presence of these chest tubes may have been protective from the development of further air leak. It would appear that isoflurane does not increase the rate of air leak in bronchospastic mechanically ventilated patients, but further conclusions or generalizations are unwarranted given the numerous variables that contribute to the development of air leak in mechanically ventilated patients.

While these data are interesting and support the notion that isoflurane appears to be an effective adjunctive measure in children with life-threatening bronchospasm, this study is not without limitations. First, the retrospective nature of the data collection is not ideal. As with any retrospective report, data collection is limited by the data which are available. Management was dictated by the clinical team caring for the patient at the time, and the available data are not standardized as would be with a prospective protocol.

Another limitation of this study is the prolonged time period that was included in this review. While including a 15 year period allowed for the collection of the largest series of pediatric patients treated with isoflurane for life-threatening bronchospasm to date, management techniques of asthma patients evolved during this time. The general strategy for the management of these patients was based on concepts and physiologic principles that remain constant, but integration of new technology, new ventilatory strategies, and evidence may have led to variation over time. In addition, there was also variability over time in the end tidal monitoring of the vaporizer output of isoflurane in series with the ventilator.

A crucial question and additional limitation to extrapolation and broad generalization of these data is the unclear trajectory and outcome for these patients if they had not been treated with isoflurane. There is no control group for comparison in this study since the vast majority of patients with bronchospasm in our institution who required mechanical ventilation during this time period were treated with isoflurane. During the period of time included in this report, isoflurane was considered in all patients with clinically evident bronchospasm requiring endotracheal intubation. Institutional experience suggested that isoflurane improves bronchospasm and shortens duration of mechanical ventilation, which coupled with the relative ease of administration of isoflurane in our PICU, likely contributed to the relatively early initiation of this therapy when patients with severe bronchospasm required mechanical ventilation. This pattern is reflected by the mean time of mechanical ventilation prior to isoflurane administration of 13 hours and limits the ability in this series

to compare the potential toxicities associated with conventional therapy with the isoflurane patients.

However, had isoflurane not been available (as is the case in many medical centers), the outcomes of these patients are not certain. Isoflurane may have led to less total mechanical ventilation time, shorter ICU stay, and improved patient outcomes, but it is equally possible that similar outcomes could have been achieved with conventional therapeutic interventions. In addition, it is possible that the use of isoflurane may have actually prolonged the duration of mechanical ventilation. In this series, mean duration of mechanical ventilation was 10.5 days, with a median of 5.5 days, compared to reported duration of mechanical ventilation in intubated asthmatic children between 1.8 and 6.3 days^{40–42}. There were a number of patients in this series that required extremely long durations of mechanical ventilation, and the majority of this time included treatment with isoflurane and post-isoflurane mechanical ventilation. It is likely that disease severity contributed to this prolonged duration of mechanical ventilation in these patients, but the impact of isoflurane on the overall management of these patients remains uncertain. In addition, the high incidence of hypotension requiring intervention is an important additional consideration as this therapy is considered.

These data support the notion that isoflurane provides bronchodilator effects for mechanically ventilated patients and may be a beneficial intervention in patients with life-threatening bronchospasm refractory to conventional therapies. Further prospective assessment of this therapeutic option would be difficult given institutional variation and limited numbers of patients, but systematic investigation could help clarify some of the unanswered questions surrounding the use of isoflurane in this setting.

Conclusions

Isoflurane can be administered in the PICU for mechanically ventilated pediatric patients with life-threatening bronchospasm, and appears to be efficacious in relieving bronchospasm and improving ventilation but is associated with a high potential in this context for transient hypotension and arrhythmias. These complications are often self-limited or manageable by pharmacologic means without discontinuation of isoflurane. The clinical impact of isoflurane in the context of life-threatening bronchospasm requiring mechanical ventilation remains unclear and vigilance is needed during its administration. As technological advances improve the potential ability of centers to provide this therapy in the PICU, further systematic evaluation of this therapy is warranted.

Acknowledgments

Financial Support: None

Dr. Smith received support from NICHD 1K23HD060040-01 and 1R18AE000028-01.

References

1. Summary Health Statistics for U.S. Children: National Health Interview Survey
2. Moorman JE, Rudd RA, Johnson CA, King M, Minor P, Bailey C, et al. National surveillance for asthma--United States, 1980–2004. *MMWR Surveill Summ.* 2007; 56(8):1–54. [PubMed: 17947969]
3. Carroll CL, Zucker AR. The increased cost of complications in children with status asthmaticus. *Pediatr Pulmonol.* 2007; 42(10):914–919. [PubMed: 17726707]
4. Schwartz SH. Treatment of status asthmaticus with halothane. *JAMA.* 1984; 251(20):2688–2689. [PubMed: 6716600]

5. Bayliff CD, Koch JP, Faclier G. The use of halothane in the treatment of status asthmaticus. *Drug Intell Clin Pharm.* 1985; 19(4):307–309. [PubMed: 4006721]
6. Bierman MI, Brown M, Muren O, Keenan RL, Glauser FL. Prolonged isoflurane anesthesia in status asthmaticus. *Critical care medicine.* 1986; 14(9):832–833. [PubMed: 3743101]
7. Parnass SM, Feld JM, Chamberlin WH, Segil LJ. Status asthmaticus treated with isoflurane and enflurane. *Anesthesia and analgesia.* 1987; 66(2):193–195. [PubMed: 3813065]
8. O'Rourke PP, Crone RK. Halothane in status asthmaticus. *Critical care medicine.* 1982; 10(5):341–343. [PubMed: 7075226]
9. Revell S, Greenhalgh D, Absalom SR, Soni N. Isoflurane in the treatment of asthma. *Anaesthesia.* 1988; 43(6):477–479. [PubMed: 3407872]
10. Johnston RG, Noseworthy TW, Friesen EG, Yule HA, Shustack A. Isoflurane therapy for status asthmaticus in children and adults. *Chest.* 1990; 97(3):698–701. [PubMed: 2306972]
11. Otte RW, Fireman P. Isoflurane anesthesia for the treatment of refractory status asthmaticus. *Ann Allergy.* 1991; 66(4):305–309. [PubMed: 2014929]
12. Hirshman CA, Edelstein G, Peetz S, Wayne R, Downes H. Mechanism of action of inhalational anesthesia on airways. *Anesthesiology.* 1982; 56(2):107–111. [PubMed: 7055323]
13. Warner DO, Vettermann J, Brichant JF, Rehder K. Direct and neurally mediated effects of halothane on pulmonary resistance in vivo. *Anesthesiology.* 1990; 72(6):1057–1063. [PubMed: 2350021]
14. Colaco CM, Crago RR, Weisbert A. Halothane for status asthmaticus in the intensive care unit--a case report. *Can Anaesth Soc J.* 1978; 25(4):329–330. [PubMed: 667675]
15. Fuchs A. The Interruption of the Asthmatic Crisis by Tribromethanol (Avertin). *The Journal of Allergy.* 1937; 8:340–346.
16. Meyer N, Schotz S. The Relief of Severe Intractable Bronchial Asthma with Cyclopropane Anesthesia. *The Journal of Allergy.* 1939; 10:239–240.
17. Rooke GA, Choi JH, Bishop MJ. The effect of isoflurane, halothane, sevoflurane, and thiopental/nitrous oxide on respiratory system resistance after tracheal intubation. *Anesthesiology.* 1997; 86(6):1294–1299. [PubMed: 9197298]
18. Tobias JD. Therapeutic applications and uses of inhalational anesthesia in the pediatric intensive care unit. *Pediatr Crit Care Med.* 2008; 9(2):169–179. [PubMed: 18477930]
19. Turner DA, Arnold JH. Improving our approach to sedation in the pediatric intensive care unit: is it time to inhale? *Pediatr Crit Care Med.* 2008; 9(2):233–234. [PubMed: 18327126]
20. Shankar V, Churchwell KB, Deshpande JK. Isoflurane therapy for severe refractory status asthmaticus in children. *Intensive Care Med.* 2006; 32(6):927–933. [PubMed: 16614808]
21. Sackey PV, Martling CR, Radell PJ. Three cases of PICU sedation with isoflurane delivered by the 'AnaConDa'. *Paediatric anaesthesia.* 2005; 15(10):879–885. [PubMed: 16176317]
22. Wheeler DS, Clapp CR, Ponaman ML, Bsn HM, Poss WB. Isoflurane therapy for status asthmaticus in children: A case series and protocol. *Pediatr Crit Care Med.* 2000; 1(1):55–59. [PubMed: 12813288]
23. Rice M, Hatherill M, Murdoch IA. Rapid response to isoflurane in refractory status asthmaticus. *Arch Dis Child.* 1998; 78(4):395–396. [PubMed: 9623413]
24. Arnold JH, Truog RD, Molengraft JA. Tolerance to isoflurane during prolonged administration. *Anesthesiology.* 1993; 78(5):985–988. [PubMed: 8387735]
25. Arnold JH, Truog RD, Rice SA. Prolonged administration of isoflurane to pediatric patients during mechanical ventilation. *Anesthesia and analgesia.* 1993; 76(3):520–526. [PubMed: 8452259]
26. Kong KL, Tyler JE, Willatts SM, Prys-Roberts C. Isoflurane sedation for patients undergoing mechanical ventilation: metabolism to inorganic fluoride and renal effects. *British journal of anaesthesia.* 1990; 64(2):159–162. [PubMed: 2317417]
27. Kong KL, Willatts SM. Isoflurane sedation in pediatric intensive care. *Critical care medicine.* 1995; 23(7):1308–1309. [PubMed: 7600844]
28. Osborne MA, Eddleston JM, McNicoll W. Inorganic fluoride concentration after long-term sedation with isoflurane. *Intensive Care Med.* 1996; 22(7):677–682. [PubMed: 8844234]

29. Sackey PV, Martling CR, Carlswald C, Sundin O, Radell PJ. Short- and long-term follow-up of intensive care unit patients after sedation with isoflurane and midazolam--a pilot study. *Critical care medicine*. 2008; 36(3):801–806. [PubMed: 18431266]
30. Spencer EM, Willatts SM. Isoflurane for prolonged sedation in the intensive care unit; efficacy and safety. *Intensive Care Med*. 1992; 18(7):415–421. [PubMed: 1469180]
31. Tanigami H, Yahagi N, Kumon K, Watanabe Y, Haruna M, Matsui J, et al. Long-term sedation with isoflurane in postoperative intensive care in cardiac surgery. *Artif Organs*. 1997; 21(1):21–23. [PubMed: 9012901]
32. Tobias JD. Tolerance, withdrawal, and physical dependency after long-term sedation and analgesia of children in the pediatric intensive care unit. *Critical care medicine*. 2000; 28(6):2122–2132. [PubMed: 10890677]
33. Kelsall AW, Ross-Russell R, Herrick MJ. Reversible neurologic dysfunction following isoflurane sedation in pediatric intensive care. *Critical care medicine*. 1994; 22(6):1032–1034. [PubMed: 8205811]
34. Barnes BJ, Hollands JM. Drug-induced arrhythmias. *Critical care medicine*. 2010; 38(6 Suppl):S188–197. [PubMed: 20502173]
35. Cripps TP, Edmondson RS. Isoflurane for anaesthesia in the dental chair a comparison of the incidence of cardiac dysrhythmias during anaesthesia with halothane and isoflurane. *Anaesthesia*. 1987; 42(2):189–191. [PubMed: 3103479]
36. Hutchison GL, Davies CA, Main G, Gray IG. Incidence of arrhythmias in dental anaesthesia: a cross-over comparison of halothane and isoflurane. *British journal of anaesthesia*. 1989; 62(5): 518–521. [PubMed: 2730824]
37. Briassoulis GC, Venkataraman ST, Vasilopoulos AG, Sianidou LC, Papadatos JH. Air leaks from the respiratory tract in mechanically ventilated children with severe respiratory disease. *Pediatr Pulmonol*. 2000; 29(2):127–134. [PubMed: 10639203]
38. Kao CC, Jain S, Guntupalli KK, Bandi V. Mechanical ventilation for asthma: a 10-year experience. *J Asthma*. 2008; 45(7):552–556. [PubMed: 18773325]
39. Zimmerman JL, Dellinger RP, Shah AN, Taylor RW. Endotracheal intubation and mechanical ventilation in severe asthma. *Critical care medicine*. 1993; 21(11):1727–1730. [PubMed: 8222690]
40. Carroll CL, Smith SR, Collins MS, Bhandari A, Schramm CM, Zucker AR. Endotracheal intubation and pediatric status asthmaticus: site of original care affects treatment. *Pediatr Crit Care Med*. 2007; 8(2):91–95. [PubMed: 17273123]
41. Chiang BL, Hsieh CT, Wang LC, Lee JH, Yu HH, Lin YT, et al. Clinical course and outcome of children with status asthmaticus treated in a pediatric intensive care unit: a 15-year review. *J Microbiol Immunol Infect*. 2009; 42(6):488–493. [PubMed: 20422133]
42. Maffei FA, van der Jagt EW, Powers KS, Standage SW, Connolly HV, Harmon WG, et al. Duration of mechanical ventilation in life-threatening pediatric asthma: description of an acute asphyxial subgroup. *Pediatrics*. 2004; 114(3):762–767. [PubMed: 15342851]

Figure 1.

This figure demonstrates the pH change during isoflurane administration. This figure compares pH values at baseline (prior to isoflurane initiation) 4 hours, 24 hours, and the time of isoflurane discontinuation. Plots represent median (line), interquartile range (box), and adjacent values (whiskers).

* p 0.05 at 4 hours compared to baseline

^ p 0.05 at 24 hours compared to 4 hours

° p 0.05 at end of therapy compared to 24 hours

Figure 2.

This figure demonstrates the pCO₂ change during isoflurane administration. This figure compares pCO₂ values at baseline (prior to isoflurane initiation) 4 hours, 24 hours, and the time of isoflurane discontinuation. Plots represent median (line), interquartile range (box), and adjacent values (whiskers).

* p = 0.05 at 4 hours compared to baseline

Table 1

Demographic Data

Demographics	
Patients (n)	31
Age (years), mean (range)	9.5 (0.4 – 23)
Male	16 (52%)
Primary Diagnosis	
Asthma/RAD	29 (94%)
Bronchiolitis	2 (6%)
Survived to Discharge	29 (94%)

Table 2

Ventilation and Isoflurane Treatment Data

Ventilation Data	Mean (range)
Time Ventilated Pre-Isoflurane (hours)	13 (0, 120)
Time Treated with Isoflurane (hours)	54 (1, 181)
Time Ventilated Post-Isoflurane (hours)	180 (0.3, 1430)
Total Time of Ventilation (hours)	252 (16, 1444)
Maximum Isoflurane Dose (%)	1.1 (0.3, 2.5)

Table 3
Mean Arterial Blood Gas and Ventilator Parameters During Isoflurane Administration

	pH +/- SEM (range)	pCO ₂ +/- SEM (range) mmHg	HCO ₃ +/- SEM (range) mmol/L	Peak Inspiratory Pressure +/- SEM (range) cmH ₂ O	FiO ₂ +/- SEM (range)
Baseline	7.13 +/- 0.02 (6.89 – 7.41)	87 +/- 5 (50 – 160)	29 +/- 2 (17 – 55)	33 +/- 1 (24 – 46)	0.74 +/- 0.04 (0.40 – 1.0)
4 hours	7.24 +/- 0.02* (6.95 – 7.45)	64 +/- 4* (25 – 134)	27 +/- 2* (18 – 52)	32 +/- 1 (20 – 46)	0.60 +/- 0.04* (0.30 – 1.0)
24 hours	7.35 +/- 0.01 [^] (7.26 – 7.44)	55 +/- 2 (40 – 82)	30 +/- 1 (22 – 45)	28 +/- 1 [^] (20 – 45)	0.48 +/- 0.04 [^] (0.35 – 0.95)
End of therapy	7.42 +/- 0.02° (7.30 – 7.55)	54 +/- 3 (39 – 74)	34 +/- 1° (26 – 44)	29 +/- 2 (14 – 41)	0.43 +/- 0.02 (0.30 – 0.60)

* p 0.05 at 4 hours compared to baseline

[^] p 0.05 at 24 hours compared to 4 hours

° p 0.05 at end of therapy compared to 24 hours

Table 4

Complications During Isoflurane Administration

Complications during Isoflurane	(n = 31)
Hypotensive Requiring Vasoactive Infusion	24 (77%)
Dopamine	19 (68%)
Epinephrine	4 (16%)
Phenylephrine	1 (3%)
Arrhythmias	3 (10%)
Neurologic Symptoms During or After Isoflurane	3 (10%)
Air Leak	1 (3%)